Pharmaceutical composition for inhibiting immune response through inducing differentiation into regulator T cells and promoting proliferation of regulator T cells
AssigneeLG Chem, Ltd.
InventorsSeok Goo Cho, Na Youn Kim, Eun Jung Kim, Keon Il Im, Jung Yeon Lim, Eun Joo Jeon
Life of this patent
Estimating the term…
Abstract
The present invention relates to new medical use of (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholine-4-yl)methyl-1H-indol-7-yl]amine, and more particularly, to a pharmaceutical composition containing the compound as an active ingredient, which is used for inhibiting an immune response, and/or for inducing differentiation into regulator T cells from undifferentiated T cells and/or promoting proliferation of regulator T cells.
Claims10
A method for suppressing immune response, comprising
- administering (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1H-indol-7-yl]amine, a pharmaceutically acceptable salt or isomer thereof to a subject in need thereof.
A method for inducing differentiation into regulatory T cell, which comprises a step of
- treating immature T cell with a composition comprising (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1H-indol-7-yl]amine, a pharmaceutically acceptable salt or isomer thereof ex vivo.
A method for promoting proliferation of regulatory T cell, which comprises a step of
- treating immature T cell with a composition comprising (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1H-indol-7-yl]amine, a pharmaceutically acceptable salt or isomer thereof ex vivo.
A method for obtaining regulatory T cell via inducing differentiation and promoting proliferation of regulatory T cell, which comprises a step of
- treating immature T cell with a composition comprising (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1H-indol-7-yl]amine, a pharmaceutically acceptable salt or isomer thereof ex vivo.
Dependencies are inferred from the claim text.